Kiniksa Pharmaceuticals Files 8-K on Financial Condition
Ticker: KNSA · Form: 8-K · Filed: 2024-02-28T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K
TL;DR
**Kiniksa Pharmaceuticals just dropped an 8-K on its financials, so expect an update on their performance.**
AI Summary
Kiniksa Pharmaceuticals, Ltd. filed an 8-K on February 28, 2024, regarding its results of operations and financial condition. This filing indicates the company is providing an update on its financial performance, likely in conjunction with an earnings release or other financial disclosure. The document was filed under the Securities Exchange Act of 1934.
Why It Matters
This filing provides an update on Kiniksa Pharmaceuticals' financial health, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing for disclosing financial results and does not inherently indicate a high risk.
Key Players & Entities
- Kiniksa Pharmaceuticals, Ltd. (company) — Registrant
- February 28, 2024 (date) — Date of earliest event reported
- 001-730430 (other) — Commission File Number
- Bermuda (other) — State of incorporation
- Securities Exchange Act of 1934 (other) — Act under which the report is filed
FAQ
What is the purpose of this 8-K filing by Kiniksa Pharmaceuticals, Ltd.?
The 8-K filing by Kiniksa Pharmaceuticals, Ltd. is to report on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' as of February 28, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on February 28, 2024.
What is the full legal name of the registrant for this 8-K?
The exact name of the Registrant as specified in its Charter is Kiniksa Pharmaceuticals, Ltd.
Under which act of the Securities Exchange Act was this report filed?
This report was filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the business address of Kiniksa Pharmaceuticals, Ltd. as listed in the filing?
The business address of Kiniksa Pharmaceuticals, Ltd. is Clarendon House, 2 Church Street, Hamilton HM11, Bermuda.
Filing Stats: 562 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-02-28 07:35:20
Key Financial Figures
- $0.000273235 — ich registered Class A Common Shares $0.000273235 par value KNSA The Nasdaq Stock Mar
Filing Documents
- tm247423d1_8k.htm (8-K) — 26KB
- tm247423d1_ex99-1.htm (EX-99.1) — 92KB
- tm247423d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-028472.txt ( ) — 305KB
- knsa-20240228.xsd (EX-101.SCH) — 3KB
- knsa-20240228_lab.xml (EX-101.LAB) — 33KB
- knsa-20240228_pre.xml (EX-101.PRE) — 22KB
- tm247423d1_8k_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 28, 2024, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2023. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1. The information contained in this Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing and except as expressly provided by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Q4 and FY2023 Earnings Press Release issued by Kiniksa Pharmaceuticals, Ltd. dated February 28, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS, LTD. Date: February 28, 2024 By: /s/ Madelyn Zeylikman Madelyn Zeylikman Senior Vice President, General Counsel and Secretary